Clinical Trial Update: Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency [Phase 2]

View source ↗

Summary

Phase 2 trial comparing paclitaxel and olaparib versus paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant therapy in HER2-negative ea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Epirubicin (epirubicin)
• Olaparib (Olaparib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: GBG Forschungs GmbH | Conditions: Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Status: COMPLETED